Yabing Zheng

612 citations
40 papers · 425 indexed · 1 hit paper · h-index 11

Yabing Zheng

38 papers receiving 421 citations

Hit Papers

PI3K/AKT/mTOR signaling pathway: an important driver and ...68202420262025204060

Peers

Yabing Zheng
Comparison fields: 5 of 67
  • Cancer Research 207
  • Oncology 143
  • Molecular Biology 233
  • Pulmonary and Respiratory Medicine 90
  • Pathology and Forensic Medicine 35
Replace Shuiping Gao with:
Shuiping Gao China
Yu Yin China
Nicola Inzerilli Italy
Gorjan Hrustanovic United States
Zhuqing Zhou China
Dongyi Wan China
Jugang Wu China
Baoxin Qian China
Lilin Ma China
Takeyasu Katada Japan
Yabing Zheng relative to Shuiping Gao China Shuiping Gao's profile →
Citations per field
00.5×1.5×
Shuiping Gao · 1×
Citations per year

Countries citing papers authored by Yabing Zheng

Since Specialization
Citations

This map shows the geographic impact of Yabing Zheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yabing Zheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yabing Zheng more than expected).

Fields of papers citing papers by Yabing Zheng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yabing Zheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yabing Zheng. The network helps show where Yabing Zheng may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Yabing Zheng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Yabing Zheng Line = papers co-authored together Yabing Zheng links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20250
2 20241
3 20245
4 20242
5
PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancerbreakdown →
202468
6 202310
7 20233
8 20224
9 20221
10 202116
11 20216
12 202116
13 20217
14 20215
15 201925
16 20170
17 20161
18 20167
19 201611
20 201557

About Yabing Zheng

Yabing Zheng is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine, having authored 40 papers that have together received 425 indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (14 papers), HER2/EGFR in Cancer Research (13 papers), Cancer Treatment and Pharmacology (8 papers), Breast Cancer Treatment Studies (8 papers), Estrogen and related hormone effects (6 papers), PI3K/AKT/mTOR signaling in cancer (5 papers), RNA modifications and cancer (4 papers) and Cancer-related molecular mechanisms research (4 papers). The work is most often cited by research in Cancer Research (207 citations), Oncology (143 citations) and Molecular Biology (233 citations). Yabing Zheng has collaborated with scholars based in China, United States and Japan. Frequent co-authors include Yu‐An Huang, Xiying Shao, Xiaojia Wang, Zhanhong Chen, Xingfei Yu, Hongjian Yang, Xiangming He, Xianghou Xia, Wen‐Ming Cao and Huanping Zhang. Their work appears in journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026